All News

single marble in group

Novel TYK2 inhibitor Zasocitinib

Brian Jaros, MD

Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and hematopoietic axes. Therefore, it is hypothesized that TYK2-targeted agents could be effective in rheumatic disease, with a potential for less off-target adverse effects. Zasocitinib is a new, oral TYK2 inhibitor generated using artificial intelligence-assisted compound design.

Read Article
PsA.Hands_.jpg

Diagnostic Delays in PsA

Caoilfhionn Marie Connolly, MD

Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study highlights a persistent and critical issue: delays in diagnosis. The study findings are stark, with about 25% of patients having erosions at diagnosis.

Read Article
psA.fil_.Hands_.jpg

Novel and Emerging Therapies in Psoriatic Arthritis

Antoni Chan, MD, PhD

Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.

Read Article
men and women

Sex related differences in PsA

Adela Castro, MD

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).

Read Article
J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa

Links:

Dr. John Cush RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR24 PsA Topic Panel Advancing Care for Psoriatic Arthritis Tune in for an engaging discussion at the ACR Annual Meeting! This expert panel will explore the latest breakthroughs and trends in Psoriatic Arthritis(PsA) research and management, providing actionable insights for… https://t.co/j0063RpVCi https://t.co/LCINZvUR5s
Dr. John Cush RheumNow ( View Tweet)
The Psoriatic March: PsA before PsO https://t.co/lRCrzdKX7Z https://t.co/eabYe3GXrM

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti IL-17 on Entheseal Biopsy in PsA Dr. Eric Dein reports on abstract 2586, presented at #ACR24 https://t.co/2JCFnB8HNq https://t.co/2MFCiNnvj2

Links:

Dr. John Cush RheumNow ( View Tweet)
Best Things I Saw Today in PsA Dr. Catherine Bakewell reviews several studies presented at #ACR24. https://t.co/eIMdoSvkFh https://t.co/aSBEgFegNr

Links:

Dr. John Cush RheumNow ( View Tweet)
Novel and Emerging Therapies in Psoriatic Arthritis Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further… https://t.co/vBexcBrTQ6 https://t.co/gWpIYKMPnx
Dr. John Cush RheumNow ( View Tweet)
PsA Ultrasound Updates Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR24. https://t.co/DZBe8uNpJS https://t.co/wIS1hUZnAS

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA Ultrasound Updates Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR2024 https://t.co/XJOuKl8lCF https://t.co/XPMlf3sOnU

Links:

Dr. John Cush RheumNow ( View Tweet)
Sex related differences in PsA Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety… https://t.co/9z9lorLtp0 https://t.co/XZRvm0S585
Dr. John Cush RheumNow ( View Tweet)
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024! View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs. https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf

Links:

Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA? We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
RheumNow Day 2 Recap: #ACR24 Highlights Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush RheumNow ( View Tweet)
PsA Potpourri Dr. Arthur Kavanaugh reviewed highlights on adult and pediatric sessions on uveitis, as well as interesting abstracts, at #ACR24 https://t.co/jsCMKHBFMk https://t.co/roZOZT3Mqd

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm

Links:

Dr. John Cush RheumNow ( View Tweet)

#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×